Shire Symposium - Beyond Hyperphosphataemia: Cardiovascular Implications of Inadequate Phosphate
Roche Symposium - Working to Improve Anemia Management: Today and in the Future
Date: Sunday April 22, 2007 Time: 12:45 - 14:15 Venue: Plenary Hall, Pavilion 5
Co-Chairs:	Francesco Locatelli, Italy Nestor Schor, Brazil
Program
12:45 - 12:50	Chairs’ Welcome and Introduction
12:50 - 13:05	The Shifting Landscape – Imitation vs. Innovation David Goldsmith, UK
13:05 - 13:20	Shaping Targets and Their Limits Tilman Drüeke, France
13:20 - 13:35	Reaching the Target Today Thomas Rath, Germany
13:35 - 13:50	Creating a New Landscape in Anemia Management Robert Provenzano, USA
13:50 - 14:05	C.E.R.A.: Targeting Hb Stability Gilbert Deray, France
14:05 - 14:15	Round Table Question and Answer

Shire Symposium - Beyond Hyperphosphataemia: Cardiovascular Implications of Inadequate Phosphate Control
Date: Sunday April 22, 2007 Time: 12:45 - 14:15 Venue: Room B1, Pavilion 5
Chair:	Juán Mariano Rodriguez Portillo, Spain
Program
12:45–13:05	Lunch
13:05–13:10	Chair’s Introduction Juán Mariano Rodriguez Portillo, Spain
13:10–13:30	The Hard Consequences of Chronic Kidney Disease: Links with Vascular Calcification Gérard London, France
13:30–13:50	Binding Phosphate: the Need for Help without Hindrance Keith Hruska, USA
13:50–14:00	Panel Discussion
14:00–14:15	Efficacy is not Enough: the Importance of Patient Adherence to Treatment Steve Riley, UK
14:15	Close

Abbott Symposium - Challenging the Current Approaches to SHPT Management
Date: Sunday April 22, 2007 Time: 12:45 - 14:15 Venue: Room 204, Pavilion 5
Chair:	Dennis Andress, USA
Program
12:45 - 13:15	Clinical Challenges of SHPT Today Rosa Moyses, Brazil
13:45 - 13:45	Selective VDR Modulators: Leading the Way in SHPT Management Jordi Bover, Spain
13:45 - 14:15	Cardioprotection: A Key Benefit of Selective VDR Modulators Dennis Andress, USA

Gambro Symposium - Dialysis Opinion Symposium on Dialysis Treatment of Acute Renal Failure

Date: Sunday April 22, 2007
Time: 12:45 - 14:15
Venue: Room 203, Pavilion 5

Chair: Claudio Ronco, Italy

Program

Why Dialysis Opinion?
Claudio Ronco, Italy

Therapy Initiation
Norbert Lameire, Belgium

Frequency and Duration
Emmanuel A. Burdmann, Brazil

Estimating and Achieving Adequate Dose
W Clark, USA

Which Anticoagulation?
Ravindra Mehta, USA

Who is Responsible?
Claudio Ronco, Italy

Results from the Opinion Poll
Ingrid Ledebo, Sweden

Discussion of the Result

Conclusion

Wyeth Symposium - Managing Risk and Improving Outcomes in Renal Transplantation
Date: Sunday April 22, 2007 Time: 12:45 - 14:15 Venue: Room 201, Pavilion 5
Chair:	Jose Medina, Brazil
Program
12:45	Chair’s Introduction Jose Medina, Brazil
12:50	The Role of CNI-Associated Nephrotoxicity in Chronic Allograft Nephropathy Renato Torres Gonçalves, Brazil
13.15	Immunosuppression - A Key Factor in Managing the Risk of Malignancy in Post-Renal Transplant Patients Josep Campistol, Spain
13.40	Sirolimus - Considering the Potential for Improved Renal Function in Renal Transplant Patients Barry Kahan, USA
14.05	Panel Discussion
14:15	Close

Fresenius Medical Care Symposium - Improving Treatment Options in Kidney Failure

Date: Sunday April 22, 2007
Time: 12:45 - 14:15
Venue: Room 202, Pavilion 5

Chairs: J. Suassana, Brazil
              Bernard Canaud, France

Program

From Uremic Toxins to the Cardiovascular Epidemic – Insights into Today’s Challenges in End Stage Renal Disease
Markus Ketteler, Germany

Improving Outcome in Dialysis Therapy – Online Haemodiafiltration as the New Gold Standard?
Bernard Canaud, France

Batch Dialysis Therapy (Genius^®) in Acute Renal Failure – A Simple Solution for a Complex Clinical Problem?
Wim van Biesen, Belgium

Novo Nordisk Symposium - Improving Biomarkers for Morbidity and Mortality in Chronic Hemodialysis Patients

Date: Monday April 23, 2007
Time: 08:00 - 09:00
Venue: Room 203, Pavilion 5

Chair: Martin Lange, Denmark

Program

Welcome and Introduction
Martin Lange, Denmark

Biomarkers for Morbidity and Mortality in Patients on Chronic Hemodialysis – Focus on Markers of Nutrition
Joel Kopple, USA

Growth Hormone Effect on Protein Homeostasis and Lean Body Mass
Alp Ikizler, USA

Effect of Growth Hormone on Biomarkers and QoL – Phase 2 Clinical Trial Results
Bo Feldt-Rasmussen, Denmark

Outcome Study Evaluating the Efficacy and Safety of Growth Hormone – Phase 3 Clinical Trial
Christian Born Djurhuus, Denmark

Conclusion and Closing Remarks
Martin Lange, Denmark

Amgen Symposium - Managing Chronic Kidney Disease in the 21st Century: New Insights, Novel Mechanisms and Clinical Research

Date: Monday April 23, 2007
Time: 12:45 - 14:15
Venue: Plenary Hall, Pavilion 5

Chair: Emmanuel A. Burdmann, Brazil

Program

Welcome, Introductions and Program Overview
Emmanuel A. Burdmann, Brazil

New Paradigms in the Treatment of Anemia in Chronic Kidney Disease
Ricardo Correa-Rotter, Mexico

Improving Outcomes in ESRD: Managing Associated Physiologic and Metabolic Abnormalities
Glenn M. Chertow, USA

Randomized Clinical Trials in Nephrology: What the Future May Hold
David Wheeler, UK

Panel Discussion

Closing Remarks and Q&A
Emmanuel A. Burdmann, Brazil

Baxter Symposium - Bringing Latin America into the World of Peritoneal Dialysis Clinical Studies
Date: Monday April 23, 2007 Time: 12:45 - 14:15 Venue: Room B1, Pavilion 5
Chair:	Jose Divino, Brazil
Program
12:45 - 12:50	Welcome and Introduction
12:50 - 13:10	Brazilian Multicenter PD Clinical Study (ECMDP) Roberto Pecoits-Filho, Brazil
13:10 - 13:30	Heart Failure Prevalence in PD Patients: Rio de la Plata Collaborative Multicenter Study (Argentina-Uruguay) Gustavo Moretta, Argentina
13:30 - 13:50	High Volume Continuous PD in the Treatment of Acute Renal Failure Andre Balbi, Brazil
13:50 - 14:10	Improved Metabolic Control and Fluid Management with Icodextrin-Based Solutions for Peritoneal Dialysis in Diabetic Patients with High Average and High Peritoneal Transport Type: a Randomized Controlled Trial Ramon Paniagua, Mexico
14:10 - 14:15	Discussion / Q&A
Portuguese and Spanish Baxter Symposium Program Baxter Symposium Registration

Genzyme Symposium - Management of CKD: Improving Outcomes via Evidence-Based Decision Making

Date: Monday April 23, 2007
Time: 12:45 - 14:15
Venue: Room 204, Pavilion 5

Chair: Eduardo Slatopolsky, USA

Program

The Pathophysiology of Phosphate in CKD
Ezequiel Bellorin-Font, Venezuela

Affecting Outcomes in CKD via Phosphate Binder Choice
Tilman B. Drüeke, France

Phosphate Binder Choice: Health and Health-Economics Implications
Donald Molony, USA

Boehringer Ingelheim Symposium - Tackling the Renal Continuum: New Data, New Prospects

Date: Monday April 23, 2007
Time: 12:45 - 14:15
Venue: Room 201, Pavilion 5

Chairs: Dick de Zeeuw, The Netherlands
              Artur Beltrame Ribeiro, Brazil

Program

Welcome and Opening Remarks
Dick de Zeeuw, The Netherlands
Artur Beltrame Ribeiro, Brazil

Current Concepts in the Pathophysiology of Early Diabetic Nephropathy
Roland E. Schmieder, Germany

Halting the Progression of Manifest Renal Disease
Stephen Bain, UK

Reducing Proteinuria: Future Clinical Possibilities and Potential Benefits
George Bakris, USA

Conclusion
Dick de Zeeuw, The Netherlands

Aspreva Symposium - Lupus Nephritis: Defining & Treating Renal Flares

Date: Monday April 23, 2007
Time: 12:45 - 14:15
Venue: Room 202, Pavilion 5

Chair: Gerald Appel

Program

Welcome & Introduction

• Introduction of speakers and their topics; why these topics are important (i.e., relevance to clinical practice)
• Presentation of accreditation and review of faculty disclosures

Flares and Remissions: The Characteristic Course of Lupus Nephritis
Gabriel Contreras

• Definition of a lupus flare: there is a need for a standardized, consensus definition
• Current inclusion/exclusion criteria for diagnosing renal manifestations
• Pathophysiology of lupus nephritis
• Managing renal flares
• Induction treatment and. maintenance therapy
• Patient management during remissions

Questions and Answers

Managing The Challenges of Lupus Nephritis
Gerald Appel

• Specific treatment goals for lupus nephritis flares
• Evidence-based treatments: what the data show(s)
• Recognizing renal flares
• The role of biologic markers
• Rationale for use of alternative pharmacotherapies to cyclophosphamide (CYC) in Lupus Nephritis

Questions and Answers

Concluding Remarks

Bayer Schering Pharma AG Symposium - Contrast Agents and Renal Impairment - What You Need to Know About CIN and NSF

Date: Tuesday April 24, 2007
Time: 12:45 - 14:15
Venue: Room B1, Pavilion 5

Chair: Miguel C. Riella, Brazil

Program

CIN - Contrast Induced Nephropathy

• I. Pathophysiology of CIN - the Importance of Viscosity
  Pontus Persson, Germany
•  
• II. What are New Studies Results Telling Us about the Renal Tolerance of
  Contrast Media?
•  
• Practical Recommendations to Avoid CIN - Results of the International Expert Panel on CIN
  Gilbert Deray, France

NSF - Nephrogenic Systemic Fibrosis

• What do We Know at the Moment about NSF and Contrast Media?
  Andrea Löwe, Germany

Biosite Symposium
Date: Monday April 23, 2007 Time: 12:45 - 14:15 Venue: Room 204, Pavilion 5
Chair:	Claudio Ronco, Italy
Program
12:45 - 12:47	Introduction and Program Agenda Chair: Claudio Ronco, Italy
12:47 - 13:07	Acute Kidney Injury Diagnosis and Staging Ravindra Mehta, USA
13:07 - 13:32	NGAL and Emerging Biomarkers of Acute Kidney Injury Prasad Devarajan, USA
13:32 - 13:57	The EVOLVE and KINGPIN Trials Emil Paganini, USA
13:57 - 14:15	Q & A

Janssen-Cilag / Ortho Biotech Symposium - In Pursuit of Optimal Outcomes in CKD Patients: From Anemia to AA Amyloidosis
Date: Monday April 23, 2007 Time: 12:45 - 14:15 Venue: Room 203, Pavilion 5
Co-Chairs:	José Portolés Pérez, Spain Elias David Neto, Brazil
Program
12:45-12:50	Welcome and Introduction José Portolés Pérez, Spain Elias David Neto, Brazil
12:50-13:05	Improving Serum Cholesterol Levels in Patients with CKD: Effects of Long-Term Epoetin Treatment Alexandros D. Tselepis, Greece
13:05-13:25	Biosimilar Epoetins in the Developing World: Results of International Survey Ajay K. Singh, USA
13:25-13:40	Assessing the Immunogenicity Profiles of Erythropoiesis-Stimulating Agents: the PRIMS Registry Angel Luis Martín de Francisco, Spain
13:40-14:00	AA Amyloidosis: the Disease, its Diagnosis, and Treatment Strategies Helen J. Lachmann, UK
14:00-14:15	Panel Discussion

Amgen / Kirin Symposium - Erythropoiesis Stimulating Agents – Past and Future

Date: Tuesday April 23, 2007
Time: 12:45 - 14:15
Venue: Room 201, Pavilion 5

Chairs: Masaomi Nangaku, Japan
              Danilo Fliser, Germany

Program

Anemia as a Risk Factor for CKD
Kunitoshi Iseki, Japan

Erythropoietin and Progression of CKD
Ferdinand H. Bahlmann, Germany

Antioxidative Effect of Erythropoietin
Pisut Katavetin, Thailand

Erythropoietin, EPCs and Vascular Repair
Ton J. Rabelink, The Netherlands

GE Healthcare Symposium - Making Sense of the Evidence in Contrast-Induced Nephropathy
Date: Monday April 23, 2007 Time: 12:45 - 14:15 Venue: Room 202, Pavilion 5
Chair:	Francesco Locatelli, Italy
Program
12:45	Chairman’s Welcome & Introduction Francesco Locatelli, Italy
12:50	Pathophysiology of CIN: An Update Norbert Lameire, Belgium
13:15	Practical Strategies to Prevent CIN: Facts and Fallacies Steven Weisbord, USA
13:40	Risk Factors, Consequences, and the Role of the Nephrologist Donal Reddan, Ireland
14:05	Discussion / Q&A
14:15	Adjourn